human ang 2 Search Results


93
Multi Sciences (Lianke) Biotech Co Ltd angpt2
Angpt2, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+Angiopoietin-2%2FANG-2+ELISA+Kit/pm38806553-126-13-14
Average 93 stars, based on 1 article reviews
angpt2 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Cusabio protein levels
Protein Levels, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+Angiopoietin+2%2CANG-2+ELISA+Kit/pm36759834-109-1-6
Average 93 stars, based on 1 article reviews
protein levels - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
MedChemExpress primary tems
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Primary Tems, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Angiopoietin-2%2C+Human/pmc13070873-48-5-17
Average 94 stars, based on 1 article reviews
primary tems - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

92
Elabscience Biotechnology human ang2 elisa kit
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Human Ang2 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+ANG2+(Angiopoietin+2)+ELISA+Kit/pm34232533-52-24-28
Average 92 stars, based on 1 article reviews
human ang2 elisa kit - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

92
MedChemExpress ang ii
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Ang Ii, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Angiopoietin-2%2C+Human/10__22514_slash_sv__2024__044-34-33-40
Average 92 stars, based on 1 article reviews
ang ii - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

90
OriGene am100096 ang2
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Am100096 Ang2, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Angiopoietin+2+(ANGPT2)+(NM_001118888)+Human+Tagged+ORF+Clone/us10517861-692-21-19
Average 90 stars, based on 1 article reviews
am100096 ang2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

92
Boster Bio angiopoietin 2
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Angiopoietin 2, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+Angiopoietin-2+ELISA+Kit+EZ-Set/pm36674749-292-0-2
Average 92 stars, based on 1 article reviews
angiopoietin 2 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

94
Sino Biological ang 2
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Ang 2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+ANG2+%2F+Angiopoietin-2+Protein/pm37936232-66-30-31
Average 94 stars, based on 1 article reviews
ang 2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
Shanghai Korain Biotech Co Ltd human angpt 2 sandwich enzymelinked immunosorbent elisa kit
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Human Angpt 2 Sandwich Enzymelinked Immunosorbent Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+Angiopoietin+2/pm38884820-74-8-17
Average 93 stars, based on 1 article reviews
human angpt 2 sandwich enzymelinked immunosorbent elisa kit - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

90
Creative BioMart seq id
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Seq Id, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Recombinant+Human+Ang-2/us10703810-661-25-33
Average 90 stars, based on 1 article reviews
seq id - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

93
Sino Biological human ang2
Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; <t>TEMs,</t> Tie2‐expressing <t>monocytes/macrophages;</t> <t>TNMs,</t> Tie2‐negative monocytes/macrophages.
Human Ang2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+Angiopoietin-2+%2F+ANG2+Protein/10__1016_slash_j__biopha__2025__118690-99-29-32
Average 93 stars, based on 1 article reviews
human ang2 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Sino Biological ang2
Design and screening of yeast display antibody (scFv) libraries. (A) Workflow overview: Degenerate oligonucleotides are computationally designed based on previously published deep mutational scanning data (DMS) ( Mason et al ., 2021 ; Koenig et al ., 2015 ) and crystal structures (PDB: 1N8Z, 4ZFF, 4ZFG), transformed into yeast, and screened by FACS for binding to antigen. The sorted populations are then used for targeted deep sequencing of the antibody variable regions. (B) The crystal structure of 4D5 scFv (grey) in complex with HER2 (blue) (PDB: 1N8Z). The amino acid positions of 4D5 targeted for combinatorial mutagenesis are highlighted in pink. (C) The 4D5 scFv library is screened for binding to HER2 antigen by FACS; dot plots show the library is fractionated into HER2-binding populations (High-, Low-, or Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S1). (D) Protein sequence logo plots represent the mutagenesis regions of the 4D5 scFV and are derived from deep sequencing of the various HER2-binding populations. (E) The crystal structure of 5A12 scFv (grey) in complex with VEGF antigen (orange) (PDB: 4ZFF). The amino acid positions of 5A12 targeted for combinatorial mutagenesis are highlighted in pink (F) The 5A12 scFv library is screened for binding to VEGF antigen by FACS; dot plots show the library is fractionated into VEGF-binding populations (High- or Low/Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S2). (G) Protein sequence logo plots represent the mutagenesis regions of the 5A12 scFV and are derived from deep sequencing of the various VEGF-binding populations. (H) The crystal structure of 5A12 scFv (grey) in complex with <t>Ang2</t> antigen (orange) (PDB: 4ZFG). The amino acid positions of 5A12 targeted for combinatorial mutagenesis are highlighted in pink (I) The 5A12 scFv library is screened for binding to VEGF antigen by FACS; dot plots show the library is fractionated into Ang2-binding populations (High- or Low/Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S3). (J) Protein sequence logo plots represent the mutagenesis regions of the 5A12 scFV and are derived from deep sequencing of the various Ang2-binding populations.
Ang2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ang+2/Human+Angiopoietin-2+%2F+ANG2+Protein+(His+Tag)%2C+Biotinylated/bio_rxiv__2023__01__30__526201-218-16-17
Average 93 stars, based on 1 article reviews
ang2 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; TEMs, Tie2‐expressing monocytes/macrophages; TNMs, Tie2‐negative monocytes/macrophages.

Journal: CNS Neuroscience & Therapeutics

Article Title: ANGPT2 /Tie2 Enhances H3K18la ‐Mediated Macrophage M2 Polarization to Promote Endothelial Cell Proliferation in the Chronically Ischaemic Brain

doi: 10.1002/cns.70879

Figure Lengend Snippet: Results of flow cytometry, western blotting, and qPCR for determining the macrophage polarization status and the expression of proangiogenic factors. (A) Representative flow cytometry histogram showing the fluorescence intensity of 6 macrophage polarization markers. (B) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in primary macrophages. (D) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (E) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in primary macrophages ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (F) Representative flow cytometry histogram showing the fluorescence intensity of macrophage polarization markers. (G) Bar charts showing the MFIs of macrophage polarization markers ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 (normalized to β‐Actin expression) in TDMs. (I) Densitometric analyses of the relative levels of iNOS, TNF‐α, IL‐6, VEGFA, IGF1, EGR1, IL‐10, and MMP9 ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). (J) qPCR results showing the relative mRNA expression of iNOS , TNF‐α , IL‐6 , VEGFA , IGF1 , EGR1 , IL‐10 , and MMP9 in TDMs ( n = 3; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. MFI, mean fluorescence intensity; TDMs, THP‐1‐derived macrophages; TEMs, Tie2‐expressing monocytes/macrophages; TNMs, Tie2‐negative monocytes/macrophages.

Article Snippet: In accordance with previous studies, primary TEMs and TNMs were treated with 100 ng/mL ANGPT2 protein (HY‐P7510; MedChemExpress, USA) for 3 h, while TDMs were exposed to the same concentration of ANGPT2 for 6 h.

Techniques: Flow Cytometry, Western Blot, Expressing, Fluorescence, Derivative Assay

Western blot and immunofluorescence staining showing the expression of relevant cytokines in the CIB of 2VO + EMS rats. (A) Representative images of triple immunofluorescence staining showing Tie2 + , CD11b + , and CD206 + cells in the CIB of each group. Bar = 50 μm. (B) Counts of M2 TEMs (Tie2 + /CD11b + /CD206 + ) in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative expression of ANGPT2, CD206, and ARG1 (normalized to β‐Actin expression). (D) Densitometric analyses of the relative expression of ANGPT2, CD206, and ARG1 ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (E) Representative images of double immunofluorescence staining showing CD31 + and Ki67 + cells in the CIB of each group. Bar = 50 μm. (F) Column chart showing the counts of CD31 + cells in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (G) Column chart showing the proportion of Ki67‐positive ECs in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative expression of CD31 (normalized to β‐Actin expression). (I) Densitometric analyses of the relative expression of CD31 ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (H) * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. The error bars represent the ±SDs. CIB: Chronically ischaemic brain; TEMs, Tie2‐expressing monocytes/macrophages.

Journal: CNS Neuroscience & Therapeutics

Article Title: ANGPT2 /Tie2 Enhances H3K18la ‐Mediated Macrophage M2 Polarization to Promote Endothelial Cell Proliferation in the Chronically Ischaemic Brain

doi: 10.1002/cns.70879

Figure Lengend Snippet: Western blot and immunofluorescence staining showing the expression of relevant cytokines in the CIB of 2VO + EMS rats. (A) Representative images of triple immunofluorescence staining showing Tie2 + , CD11b + , and CD206 + cells in the CIB of each group. Bar = 50 μm. (B) Counts of M2 TEMs (Tie2 + /CD11b + /CD206 + ) in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (C) Representative western blot showing the relative expression of ANGPT2, CD206, and ARG1 (normalized to β‐Actin expression). (D) Densitometric analyses of the relative expression of ANGPT2, CD206, and ARG1 ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (E) Representative images of double immunofluorescence staining showing CD31 + and Ki67 + cells in the CIB of each group. Bar = 50 μm. (F) Column chart showing the counts of CD31 + cells in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (G) Column chart showing the proportion of Ki67‐positive ECs in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (H) Representative western blot showing the relative expression of CD31 (normalized to β‐Actin expression). (I) Densitometric analyses of the relative expression of CD31 ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (H) * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. The error bars represent the ±SDs. CIB: Chronically ischaemic brain; TEMs, Tie2‐expressing monocytes/macrophages.

Article Snippet: In accordance with previous studies, primary TEMs and TNMs were treated with 100 ng/mL ANGPT2 protein (HY‐P7510; MedChemExpress, USA) for 3 h, while TDMs were exposed to the same concentration of ANGPT2 for 6 h.

Techniques: Western Blot, Immunofluorescence, Staining, Expressing, Double Immunofluorescence Staining

Behavioral test, western blotting, and immunofluorescence results in 2VO + EMS rats 4‐week post‐modeling. (A) Quantitative analysis of the percentage of recognition preference for the novel object in each group rats in NORT test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (B) Representative image showing the swimming paths in each group rats during the MWM test. (C) Line chart showing the average escape latencies in each group rats during the MWM test ( n = 6; two‐way ANOVA and Tukey's multiple comparisons test; ***: TEMs vs. TEMs ANGPT2 , ****: TEMs ANGPT2 vs. TEMs ANGPT2+Oxamate , TEMs ANGPT2 vs. TEMs ANGPT2+C646 , TEMs ANGPT2 vs. TEMs ANGPT2+LPS ). (D) Quantitative analysis of the time spent in target quadrant in each group rats during the MWM test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (E) Quantitative analysis of the number of platform crossings in each group rats during the MWM test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (F) Quantitative analysis of the average swimming speed in each group rats during the MWM test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (G) Representative western blot showing the relative expression of CD31 (normalized to β‐Actin expression). (H) Densitometric analyses of the relative expression of CD31 ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (I) Representative images of double immunofluorescence staining showing CD31 + and Ki67 + cells in the CIB of each group. Bar = 50 μm. (J) Column chart showing the counts of CD31 + cells in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (K) Column chart showing the proportion of Ki67‐positive ECs in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 2VO, 2‐vessel occlusion; EMS, encephalomyosynangiosis; MWM, Morris water maze; NORT, novel object recognition test; TEMs, Tie2‐expressing monocytes/macrophages.

Journal: CNS Neuroscience & Therapeutics

Article Title: ANGPT2 /Tie2 Enhances H3K18la ‐Mediated Macrophage M2 Polarization to Promote Endothelial Cell Proliferation in the Chronically Ischaemic Brain

doi: 10.1002/cns.70879

Figure Lengend Snippet: Behavioral test, western blotting, and immunofluorescence results in 2VO + EMS rats 4‐week post‐modeling. (A) Quantitative analysis of the percentage of recognition preference for the novel object in each group rats in NORT test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (B) Representative image showing the swimming paths in each group rats during the MWM test. (C) Line chart showing the average escape latencies in each group rats during the MWM test ( n = 6; two‐way ANOVA and Tukey's multiple comparisons test; ***: TEMs vs. TEMs ANGPT2 , ****: TEMs ANGPT2 vs. TEMs ANGPT2+Oxamate , TEMs ANGPT2 vs. TEMs ANGPT2+C646 , TEMs ANGPT2 vs. TEMs ANGPT2+LPS ). (D) Quantitative analysis of the time spent in target quadrant in each group rats during the MWM test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (E) Quantitative analysis of the number of platform crossings in each group rats during the MWM test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (F) Quantitative analysis of the average swimming speed in each group rats during the MWM test ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (G) Representative western blot showing the relative expression of CD31 (normalized to β‐Actin expression). (H) Densitometric analyses of the relative expression of CD31 ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (I) Representative images of double immunofluorescence staining showing CD31 + and Ki67 + cells in the CIB of each group. Bar = 50 μm. (J) Column chart showing the counts of CD31 + cells in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). (K) Column chart showing the proportion of Ki67‐positive ECs in each group ( n = 6; one‐way ANOVA and Tukey's multiple comparisons test). The error bars represent the ± SDs. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 2VO, 2‐vessel occlusion; EMS, encephalomyosynangiosis; MWM, Morris water maze; NORT, novel object recognition test; TEMs, Tie2‐expressing monocytes/macrophages.

Article Snippet: In accordance with previous studies, primary TEMs and TNMs were treated with 100 ng/mL ANGPT2 protein (HY‐P7510; MedChemExpress, USA) for 3 h, while TDMs were exposed to the same concentration of ANGPT2 for 6 h.

Techniques: Western Blot, Immunofluorescence, Expressing, Double Immunofluorescence Staining

Design and screening of yeast display antibody (scFv) libraries. (A) Workflow overview: Degenerate oligonucleotides are computationally designed based on previously published deep mutational scanning data (DMS) ( Mason et al ., 2021 ; Koenig et al ., 2015 ) and crystal structures (PDB: 1N8Z, 4ZFF, 4ZFG), transformed into yeast, and screened by FACS for binding to antigen. The sorted populations are then used for targeted deep sequencing of the antibody variable regions. (B) The crystal structure of 4D5 scFv (grey) in complex with HER2 (blue) (PDB: 1N8Z). The amino acid positions of 4D5 targeted for combinatorial mutagenesis are highlighted in pink. (C) The 4D5 scFv library is screened for binding to HER2 antigen by FACS; dot plots show the library is fractionated into HER2-binding populations (High-, Low-, or Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S1). (D) Protein sequence logo plots represent the mutagenesis regions of the 4D5 scFV and are derived from deep sequencing of the various HER2-binding populations. (E) The crystal structure of 5A12 scFv (grey) in complex with VEGF antigen (orange) (PDB: 4ZFF). The amino acid positions of 5A12 targeted for combinatorial mutagenesis are highlighted in pink (F) The 5A12 scFv library is screened for binding to VEGF antigen by FACS; dot plots show the library is fractionated into VEGF-binding populations (High- or Low/Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S2). (G) Protein sequence logo plots represent the mutagenesis regions of the 5A12 scFV and are derived from deep sequencing of the various VEGF-binding populations. (H) The crystal structure of 5A12 scFv (grey) in complex with Ang2 antigen (orange) (PDB: 4ZFG). The amino acid positions of 5A12 targeted for combinatorial mutagenesis are highlighted in pink (I) The 5A12 scFv library is screened for binding to VEGF antigen by FACS; dot plots show the library is fractionated into Ang2-binding populations (High- or Low/Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S3). (J) Protein sequence logo plots represent the mutagenesis regions of the 5A12 scFV and are derived from deep sequencing of the various Ang2-binding populations.

Journal: bioRxiv

Article Title: Meta Learning Improves Robustness and Performance in Machine Learning-Guided Protein Engineering

doi: 10.1101/2023.01.30.526201

Figure Lengend Snippet: Design and screening of yeast display antibody (scFv) libraries. (A) Workflow overview: Degenerate oligonucleotides are computationally designed based on previously published deep mutational scanning data (DMS) ( Mason et al ., 2021 ; Koenig et al ., 2015 ) and crystal structures (PDB: 1N8Z, 4ZFF, 4ZFG), transformed into yeast, and screened by FACS for binding to antigen. The sorted populations are then used for targeted deep sequencing of the antibody variable regions. (B) The crystal structure of 4D5 scFv (grey) in complex with HER2 (blue) (PDB: 1N8Z). The amino acid positions of 4D5 targeted for combinatorial mutagenesis are highlighted in pink. (C) The 4D5 scFv library is screened for binding to HER2 antigen by FACS; dot plots show the library is fractionated into HER2-binding populations (High-, Low-, or Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S1). (D) Protein sequence logo plots represent the mutagenesis regions of the 4D5 scFV and are derived from deep sequencing of the various HER2-binding populations. (E) The crystal structure of 5A12 scFv (grey) in complex with VEGF antigen (orange) (PDB: 4ZFF). The amino acid positions of 5A12 targeted for combinatorial mutagenesis are highlighted in pink (F) The 5A12 scFv library is screened for binding to VEGF antigen by FACS; dot plots show the library is fractionated into VEGF-binding populations (High- or Low/Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S2). (G) Protein sequence logo plots represent the mutagenesis regions of the 5A12 scFV and are derived from deep sequencing of the various VEGF-binding populations. (H) The crystal structure of 5A12 scFv (grey) in complex with Ang2 antigen (orange) (PDB: 4ZFG). The amino acid positions of 5A12 targeted for combinatorial mutagenesis are highlighted in pink (I) The 5A12 scFv library is screened for binding to VEGF antigen by FACS; dot plots show the library is fractionated into Ang2-binding populations (High- or Low/Non-binding) based on fluorescence intensity. Multiple rounds of FACS are performed (Fig. S3). (J) Protein sequence logo plots represent the mutagenesis regions of the 5A12 scFV and are derived from deep sequencing of the various Ang2-binding populations.

Article Snippet: The 5A12 library was first incubated with either 0.5 nM VEGF (Acro, VE5-H82Q0-200ug) or 12 nM Ang2 (Sino Biological, 10691-H08S-B) plus Streptavidin-AlexaFluor647 (Bioloegend, 405237) for 30 minutes at 4 C. Following the fist stain, cells were centrifuged at 8000 G for 30 seconds and washed once before incubation with 1ng/μL anti-FLAG-PE for 30 minutes at 4 C. Following staining, cells were washed twice and kept on ice and away from light until sorting. scFv expressing (FLAG+) cells in the 4D5 library were sorted by FACS (BD Aria Fusion) first into HER2 binding and non-binding fractions, then into three populations based on AlexaFluor647-conjugated HER2 Mean Fluorescent Intensity: High, Low, and Negative. scFv expressing (FLAG+) cells in the 5A12 library were sorted by FACS (BD Aria Fusion) into High binding (VEGF+ or Ang2+) or Low/Non-binding (VEGF- or Ang2-) populations.

Techniques: Transformation Assay, Binding Assay, Sequencing, Mutagenesis, Fluorescence, Derivative Assay

Meta learning applied to supervised machine learning models trained to predict multi-antigen binding classification using yeast antibody (scFv) sequence data with largely single-antigen binding classification labels. (A) Schematic representation of machine learning task. The training set is constructed from deep sequencing of 5A12 libraries following the final round of the VEGF FACS screen (Fig. S2). Positive (High-binding) and negative (Low/Non-binding) VEGF labels are retained and sequences are arbitrarily assigned an Ang2 binding classification. Test and meta sets consist of 5A12 variants with binding labels for both targets and are batched by combining deep sequencing from both VEGF and Ang2 final round FACS screens (Fig. S2, S3). (B,C, and D) Meta learning and baseline prediction performance (Matthew’s Correlation Coefficient) as a function of the number of training samples. FT refers to Fine-Tune Baseline. Points correspond to mean performance and shaded regions to 95 % confidence intervals across 3 random seeds. Performance curves plotted for meta sets consisting of 32 (bright yellow), 96 (dark yellow), 288 (red), and 864 (purple) sequences.

Journal: bioRxiv

Article Title: Meta Learning Improves Robustness and Performance in Machine Learning-Guided Protein Engineering

doi: 10.1101/2023.01.30.526201

Figure Lengend Snippet: Meta learning applied to supervised machine learning models trained to predict multi-antigen binding classification using yeast antibody (scFv) sequence data with largely single-antigen binding classification labels. (A) Schematic representation of machine learning task. The training set is constructed from deep sequencing of 5A12 libraries following the final round of the VEGF FACS screen (Fig. S2). Positive (High-binding) and negative (Low/Non-binding) VEGF labels are retained and sequences are arbitrarily assigned an Ang2 binding classification. Test and meta sets consist of 5A12 variants with binding labels for both targets and are batched by combining deep sequencing from both VEGF and Ang2 final round FACS screens (Fig. S2, S3). (B,C, and D) Meta learning and baseline prediction performance (Matthew’s Correlation Coefficient) as a function of the number of training samples. FT refers to Fine-Tune Baseline. Points correspond to mean performance and shaded regions to 95 % confidence intervals across 3 random seeds. Performance curves plotted for meta sets consisting of 32 (bright yellow), 96 (dark yellow), 288 (red), and 864 (purple) sequences.

Article Snippet: The 5A12 library was first incubated with either 0.5 nM VEGF (Acro, VE5-H82Q0-200ug) or 12 nM Ang2 (Sino Biological, 10691-H08S-B) plus Streptavidin-AlexaFluor647 (Bioloegend, 405237) for 30 minutes at 4 C. Following the fist stain, cells were centrifuged at 8000 G for 30 seconds and washed once before incubation with 1ng/μL anti-FLAG-PE for 30 minutes at 4 C. Following staining, cells were washed twice and kept on ice and away from light until sorting. scFv expressing (FLAG+) cells in the 4D5 library were sorted by FACS (BD Aria Fusion) first into HER2 binding and non-binding fractions, then into three populations based on AlexaFluor647-conjugated HER2 Mean Fluorescent Intensity: High, Low, and Negative. scFv expressing (FLAG+) cells in the 5A12 library were sorted by FACS (BD Aria Fusion) into High binding (VEGF+ or Ang2+) or Low/Non-binding (VEGF- or Ang2-) populations.

Techniques: Binding Assay, Sequencing, Construct